Table 1.
Baseline patient characteristics and demographics in HORIZON-PFT patients and in female patients enrolled in the HORIZON-RFT
| HORIZON-PFT* | HORIZON-RFT | |||
|---|---|---|---|---|
|
|
||||
| Variable | Placebo, N=3861 |
Zoledronic acid, N=3875 |
Placebo, N=802 |
Zoledronic acid, N=817 |
| Age, years ±SD | 73.0±5.40 | 73.1±5.34 | 75.2±9.60 | 75.0±9.15 |
|
Body mass index,
kg/m2±SD |
25.4±4.3 | 25.1±4.3 | 24.8±4.57 | 24.8±4.48 |
| Region, n (%) | ||||
| Western Europe | 1162 (30.1) | 1160 (29.9) | 270 (33.7) | 279 (34.1) |
| Eastern Europe | 772 (20.0) | 774 (20.0) | 195 (24.3) | 210 (25.7) |
| North America | 765 (19.8)† | 766 (19.8)† | 229 (28.5) | 216 (26.4) |
| Latin America | 622 (16.1) | 625 (16.1) | 108 (13.5) | 112 (13.7) |
| Asia | 540 (14.0) | 550 (14.2) | NA | NA |
| Femoral neck T-score, n (%) | ||||
| ≤−2.5 | 2734 (70.8) | 2814 (72.6) | 342 (42.6) | 354 (43.3) |
| >2.5 to −1.5 | 1073 (27.8) | 1002 (25.9) | 277 (34.5) | 269 (32.9) |
| >1.5 | 38 (1.0) | 35 (0.9) | 84 (10.5) | 91 (11.1) |
| Missing | 16 (0.4) | 24 (0.6) | 99 (12.3) | 103 (12.6) |
*
29 patients from the HORIZON-PFT were excluded from this pooled analysis as they were enrolled at a site whose participation was terminated during the study.
†
Plus Oceania.
BMD, bone mineral density; HORIZON-PFT, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial; HORIZON-RFT, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Recurrent Fracture Trial; NA, not applicable; SD, standard deviation.